Idenix to receive $20m milestone payment from ViiV Healthcare
Idenix said that, in February 2009, it licensed to GlaxoSmithKline (GSK) on a worldwide basis, a non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidate, ‘761, for the treatment of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.